# TGRX-326 Pharmacokinetic Mass Balance

> **NCT06438367** · PHASE1 · COMPLETED · sponsor: **Shenzhen TargetRx Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** [14C]TGRX-326

## Key facts

- **NCT ID:** NCT06438367
- **Lead sponsor:** Shenzhen TargetRx Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-26
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-07-21
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06438367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06438367, "TGRX-326 Pharmacokinetic Mass Balance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06438367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*